Product Description
Rock425 (CCR4-IL2 IT) is genetically engineered to contain both anti-human CCR4 scFv and human IL2 fused to truncated diphtheria toxin. It is expressed using a proprietary diphtheria toxin-resistant P. pastoris yeast expression system. (Sourced from: https://rockimmune.com/#:~:text=Leading%20Drug%20Candidate,-Rock425%20(CCR4%2DIL2&text=Show%20More-,Rock425%20(CCR4%2DIL2%20IT)%20is%20genetically%20engineered%20to%20contain,pastoris%20yeast%20expression%20system.)
Mechanisms of Action: CCR4 Inhibitor,IL2 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Rock Immune
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for ROCK-425](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: T-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|